Amgen (AMGN) and Incyte (INCY) on Torvanta's measures: AMGN grades higher on 2 of the 4 factor families and INCY on 2.
| AMGN | INCY | |
|---|---|---|
| Value grade | C+ | B+ |
| Growth grade | C+ | B |
| Profitability grade | A- | n/a |
| Momentum grade | B+ | C- |
| Market value | $233.8B | n/a |
| P/E (trailing) | 26.9x | n/a |
| Forward P/E (Torvanta model estimate) | Subscribers | Subscribers |
| Revenue, last 12 months | $38.1B | $5.4B |
| Revenue growth (y/y) | +9% | n/a |
| Operating margin | 30.0% | 30.0% |
| Return on invested capital | 17.7% | n/a |
| Free-cash-flow yield | 4.4% | 7.8% |
| Total return, 1 year | +50.2% | +29.5% |
| Total return, 3 years | +64.9% | +96.2% |
Full AMGN analysis · Full INCY analysis
Amgen (AMGN) and Incyte (INCY) on Torvanta's measures: AMGN grades higher on 2 of the 4 factor families and INCY on 2. Which fits an investor depends on their goals; this is research, not a recommendation. Subscribers see where the model ranks each and its expected return.
On trailing earnings AMGN trades at 26.9x and INCY at n/a; their value grades are C+ and B+ against their sectors.
Subscribers get a rating, a fair value estimate, a 12-month target and a risk read for every S&P 500 company, Torvanta's earnings estimates, and three model portfolios (Active, Adaptive and Patient) with every trade sized and explained. A free account includes 3 full Stock Analyst reports a month.
See plans Or get the free weekly newsletterTorvanta is research only - not investment advice and not a recommendation to buy or sell any security. Grades describe a company's reported data against its sector; they are not the model's view, change as data changes and can be wrong. Financial figures come from the company's SEC filings; returns include reinvested dividends. Past performance does not predict future results.
All stock ratings · Stock lists · AI stock research · Model portfolio · Research · Disclaimer